324 related articles for article (PubMed ID: 35412625)
1. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
4. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
[TBL] [Abstract][Full Text] [Related]
5. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
[TBL] [Abstract][Full Text] [Related]
6. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
8. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
[TBL] [Abstract][Full Text] [Related]
9. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
10. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
11. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
[No Abstract] [Full Text] [Related]
13. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study.
Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T
Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
15. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
[TBL] [Abstract][Full Text] [Related]
16. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
Buonomo AR; Filippo ID; Esposito N; Saccone G; Nobile M; Viceconte G; Villari R; Carlo CD; Bifulco G; Gentile I
Am J Perinatol; 2024 Feb; 41(3):365-367. PubMed ID: 37072016
[TBL] [Abstract][Full Text] [Related]
17. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
Riccardo BA; Gabriele S; Nunzia E; Isabella DF; Biagio P; Maria F; Emanuela Z; Agnese G; Nicola SM; Giulio V; Riccardo S; Giuseppe B; Ivan G
Am J Perinatol; 2024 May; 41(S 01):e612-e616. PubMed ID: 35973799
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
Bierle DM; Ganesh R; Razonable RR
J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
[TBL] [Abstract][Full Text] [Related]
19. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
Razonable RR; Pawlowski C; O'Horo JC; Arndt LL; Arndt R; Bierle DM; Borgen MD; Hanson SN; Hedin MC; Lenehan P; Puranik A; Seville MT; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Ganesh R
EClinicalMedicine; 2021 Oct; 40():101102. PubMed ID: 34485873
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
